IL161600A0 - Compounds and method for the treatment of over-active bladder - Google Patents

Compounds and method for the treatment of over-active bladder

Info

Publication number
IL161600A0
IL161600A0 IL16160002A IL16160002A IL161600A0 IL 161600 A0 IL161600 A0 IL 161600A0 IL 16160002 A IL16160002 A IL 16160002A IL 16160002 A IL16160002 A IL 16160002A IL 161600 A0 IL161600 A0 IL 161600A0
Authority
IL
Israel
Prior art keywords
compounds
sup
treatment
over
active bladder
Prior art date
Application number
IL16160002A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL161600A0 publication Critical patent/IL161600A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
IL16160002A 2001-11-02 2002-11-01 Compounds and method for the treatment of over-active bladder IL161600A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder
PCT/SE2002/001991 WO2003037889A1 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
IL161600A0 true IL161600A0 (en) 2004-09-27

Family

ID=20285984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16160002A IL161600A0 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of over-active bladder

Country Status (16)

Country Link
US (1) US7368461B2 (xx)
EP (1) EP1444220B1 (xx)
JP (1) JP2005511571A (xx)
KR (1) KR20040053239A (xx)
CN (1) CN1610676A (xx)
AT (1) ATE353886T1 (xx)
BR (1) BR0213832A (xx)
CA (1) CA2465429A1 (xx)
DE (1) DE60218203T2 (xx)
ES (1) ES2282491T3 (xx)
IL (1) IL161600A0 (xx)
MX (1) MXPA04004075A (xx)
NO (1) NO20042138L (xx)
SE (1) SE0103795D0 (xx)
WO (1) WO2003037889A1 (xx)
ZA (1) ZA200403206B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
CN112915266B (zh) * 2021-02-05 2021-11-09 武汉磁济科技有限公司 一种人工膀胱铁磁复合体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) * 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
AU3061499A (en) * 1998-12-04 2000-06-26 Rimma Iliinichna Ashkinazi Aryl- and heteroarylamides of carboalkoxysulfanilic acids
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
EP1444220A1 (en) 2004-08-11
EP1444220B1 (en) 2007-02-14
WO2003037889A1 (en) 2003-05-08
DE60218203T2 (de) 2008-01-03
KR20040053239A (ko) 2004-06-23
NO20042138L (no) 2004-05-25
ATE353886T1 (de) 2007-03-15
CN1610676A (zh) 2005-04-27
US7368461B2 (en) 2008-05-06
ES2282491T3 (es) 2007-10-16
SE0103795D0 (sv) 2001-11-02
US20050203113A1 (en) 2005-09-15
WO2003037889A8 (en) 2004-05-06
CA2465429A1 (en) 2003-05-08
BR0213832A (pt) 2004-08-31
DE60218203D1 (de) 2007-03-29
JP2005511571A (ja) 2005-04-28
MXPA04004075A (es) 2004-07-23
ZA200403206B (en) 2005-02-22

Similar Documents

Publication Publication Date Title
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
EP2289492A3 (en) Naltrexone hydrochloride compositions
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
DE60112974D1 (en) Carbolinderivate
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
NO20012194L (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
TR200102178T2 (tr) CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
WO2001039723A3 (en) Triazospiro compounds having nociceptin receptor affinity
IL161600A0 (en) Compounds and method for the treatment of over-active bladder
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
WO2000047547A3 (en) Cycloalkyl amine compounds and uses thereof
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
AU2001274786A1 (en) Method for the treatment of overactive bladder
MXPA04004071A (es) Metodo para tratamiento de vejiga hiperactiva.
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
AU2001263329A1 (en) Crf receptor antagonists and methods relating thereto
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
EP1584333A3 (en) Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
AU2002323480A1 (en) Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents